Skip to content
Peptigraph home
Shop Peptides50% off*

Retatrutide for Joint Pain: What the Evidence Shows

What human and animal studies show about Retatrutide for joint pain, how strong that evidence is, and what is still unproven.

Medical review pendingGLP-1 / GIP / glucagon triple agonistUpdated
Strongest evidence
Human RCT
Human studies
1
with an outcome for joint pain, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for joint pain, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
1
with an outcome for joint pain

Evidence for joint pain

Each row is an outcome related to joint pain from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Retatrutide for joint pain: outcomes in published studies
OutcomeResultStudy typeSource
Knee osteoarthritis pain (WOMAC)In people with knee osteoarthritis the WOMAC pain score changed by -3.2, -3.5 and -3.6 across the retatrutide groups versus -1.9 with placebo (hybrid estimand).Human RCTn = 2339The New England journal of medicine 2026, PMID 42814954

Retatrutide and joint pain are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2026, PMID 42814954

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Joint pain, knee osteoarthritis and what was registered

MedlinePlus says arthritis may cause joint pain and swelling, and that osteoarthritis is its most common type.[4]

A dedicated phase 3 registry entry covers retatrutide once weekly in people with obesity or overweight and osteoarthritis of the knee.[5]

That knee trial's first primary outcome is the change in the WOMAC pain subscale score at week 68.[5]

The large phase 3 obesity trial registered a WOMAC pain score for its knee osteoarthritis subset as a primary outcome at week 80.[6]

What the published phase 3 pain results say

Among 574 participants with knee osteoarthritis, the primary pain outcome used the WOMAC score, which runs from 1 to 10 with higher scores meaning worse pain.[2]

For the hybrid estimand, pain scores changed by -3.2, -3.5 and -3.6 on retatrutide against -1.9 on placebo, with differences of -1.6 and -1.8 points from placebo.[2]

For the intention-to-treat estimand the pain changes were -3.4, -3.9 and -4.1 on retatrutide against -2.5 on placebo.[2]

Is joint pain a reported side effect

The phase 3 obesity abstract names gastrointestinal events as the most common adverse events and does not mention joint pain.[2]

Other peptides people research for joint pain

TirzepatideSemaglutideBPC-157TesamorelinWolverineKLOWGLOW
All peptides for joint pain, compared

Common questions

Does Retatrutide help with joint pain?

The strongest study we summarise for joint pain is human rct evidence, across 1 study with an outcome for joint pain. A trial result is not an approval; see the legal status.

Is Retatrutide approved for joint pain?

No. Retatrutide is not FDA approved for any use, including joint pain.

What is the best peptide for joint pain?

There is no single answer. Our joint pain overview compares each candidate by evidence grade and legal status rather than by popularity.

Does retatrutide help knee osteoarthritis pain?

In the phase 3 obesity trial's knee osteoarthritis subgroup, the authors report reduced pain compared with placebo.[2]

Does retatrutide cause back pain?

None of the cached retatrutide abstracts for this page reports back pain; the phase 3 abstract names gastrointestinal events as the most common adverse events.[2]

More on Retatrutide

DosageDoses used in published trials, the titration pattern and a units chart.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.BenefitsClaimed benefits next to what published studies measured.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial (Jastreboff AM et al.)New England Journal of Medicine · 2023PMID 37366315Accessed 2 Oct 2026
  2. 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1; Jastreboff AM et al.)New England Journal of Medicine · 2026PMID 42814954Accessed 2 Oct 2026
  3. 3A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (NCT04881760; arms and posted results)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
  4. 4Official web pageOfficial web page · web page
  5. 5A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled TrialClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
  6. 6A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.